Radioactive iodide uptake (RAIU) 
Introduction
Iodine is an essential component of thyroid hormone. Since iodine is a rare element, the thyroid gland has an effective way to sequester iodine from blood circulation for the synthesis of thyroid hormones. The iodide uptake activity in thyroidal follicular cells is mediated by sodium iodide symporter (NIS), which is an intrinsic membrane protein with 13 putative transmembrane domains. [1] [2] [3] Electrophysiological studies revealed that NIS transports one I Ϫ ion with two Na + ions into cells. 4 Animal studies and clinical observations showed that NIS-expressing tissues could also concentrate pertechnetate (TcO 4 Ϫ ), 5 perrhenate (ReO 4 Ϫ ), 5, 6 and astatide (At Ϫ ). 7, 8 NIS is expressed primarily in thyroid tissues, but variable degrees of NIS expression were observed in various tissues including nasal mucosa, stomach, salivary glands, and lactating breast tissues.
Radioiodide concentrating activity in the thyroid has provided a mechanism for imaging and treatment by specific radionuclides for patients with thyroid cancers after thyroidectomy. Following molecular cloning of NIS, 1, 2 we and others demonstrated that active iodide uptake can be induced in a variety of cells by NIS gene transfer using transient 1, 9 or stable transfection. 9, 10 Based on these observations, we hypothesized that efficient NIS gene transfer to tumor cells will allow intracellular radioiodide accumulation following radioiodide administration, and thereby result in better tumor control.
To test this hypothesis, we previously studied the expression and activity of human NIS (hNIS) in cultured human glioma cells by adenovirus-mediated gene delivery in vitro and in vivo. 11 Delivery of exogenous hNIS in vitro resulted in more than a 120-fold increase of RAIU in U1240 cells infected with recombinant adenovirus carrying hNIS, compared with parental cells. Intratumoral injection of rAd-CMV-hNIS into subcutaneous xenografts of U251 human gliomas resulted in an approximately 25-fold increase of 125 I accumulation over the spleen or saline-injected tumors. 11 Similarly, other investigators have also reported that either retrovirus-or adenovirusmediated gene delivery of NIS to various human cancer cell lines resulted in increased radioiodide uptake activity in cultured cells, as well as in vivo imaging of xenografts expressing exogenous NIS. 12, 13 In addition, enhanced tumor-killing effects of 131 I after NIS gene transfer have been demonstrated by in vitro clonogenic assays 12, 14 and by decreased tumor volume in nude mice carrying xeno-grafts. 9 Here we present findings from our studies of tumor imaging in vivo and the therapeutic efficacy of 131 I in rats bearing intracerebral F98 gliomas expressing exogenous hNIS.
Results

Radioiodide uptake activity is increased in the retrovirus-mediated, hNIS-transduced F98 glioma cells
We have constructed a recombinant retrovirus containing hNIS (L-hNIS-SN) (Figure 1a) . With hNIS expression driven by the Moloney murine leukemia virus LTR promoter. The SV40 promoter-driven 'neomycin-resistant' gene was used to select the transduced clones. NIS function in the hNIS-transduced F98 glioma cells was tested in vitro by radioiodide uptake assay. RAIU in hNIStransduced F98 rat glioma cells was 40-fold higher than parental F98 cells (Figure 1b) , and the induced RAIU was inhibited by sodium perchlorate (NaClO 4 ), a NIS-specific inhibitor. As a negative control, F98/LXSN, F98 cells transduced with a recombinant retrovirus containing LXSN empty retroviral vector, were also selected and used for subsequent animal studies of retrovirusmediated gene transfer. F98/hNIS tumor sizes >4.5 mm in diameter are detectable by 99m TcO 4 scintigraphy In addition to the thyroid and parotid glands, intense 99m TcO 4 uptake was found in the intracerebral F98/hNIS gliomas in both vertex and lateral views (Figure 3a) . In contrast, no 99m TcO 4 uptake was found in parental F98 tumors. For rats implanted with 10 5 F98/hNIS glioma cells, the intracerebral tumor could be detected as early as 11 days after implantation (Figure 3b ), at which time the tumor measured 4.5 × 3.8 mm in the largest tumor area at postmortem examination.
I is retained in the F98/hNIS tumors up to 24 h Serial
123
I images were performed to determine the retention of radioiodide in the hNIS-transduced tumors ( Figure 4a ). Top panels in Figure 4a show the serial 123 I images acquired by pinhole collimator in vertex view, and the bottom panels show the simultaneous images acquired with a planar collimator in ventral view. Radioiodide uptake was evident in F98/hNIS gliomas up to 24 h after injection. However, 123 I uptake was barely detectable in F98/hNIS gliomas by 37 h after injection. Based on the time activity curve shown in Figure 4b , the biological half-life of 123 I in F98/hNIS gliomas was estimated to be 10 h. In comparison, the biological half-life of 123 I in the thyroid was estimated to be greater than 20 h.
RAIU and NIS expression in the rat thyroid can be reduced by thyroxin (T4) supplementation
Rats fed a T4-supplemented diet are expected to have reduced RAIU in thyroid, as the endogenous NIS expression and activity in thyroid tissues is TSH-dependent. As shown in Figure 5a , thyroid is not detectable in rats fed a T4-supplemented diet for 11 days. In comparison, thyroid is readily detectable by 99m TcO 4 scintigraphy in rats fed a normal diet. By Western blot analysis, NIS glycoprotein was detected in the thyroids from rats fed a normal diet, but barely detected in the thyroids from rats fed a T4-supplemented diet (Figure 5b) . Therefore, lack of RAIU in the thyroid gland of T4-supplemented rats was mainly due to decreased NIS protein expression. longer, P Ͻ 0.01), and also compared with that of rats with F98/hNIS tumors without 131 I treatment (6 days longer, P Ͻ 0.05). There was no significant difference in the sizes of intracerebral glioma at the time of death among rats in the F98/LXSN with 131 I treatment group (8.7 ± 1.6 × 6.4 ± 1.6 mm), the F98/hNIS without 131 I treatment group (8.1 ± 2.3 × 6.7 ± 2.1 mm) and F98/hNIS with 131 I treatment group (8.5 ± 1.9 × 6.1 ± 1.5 mm). One rat in the F98/hNIS with 131 I treatment group was killed on day 65 due to hind limb paralysis, with a tumor size of 4.0 × 3.5 mm.
Survival was increased in rats with F98/hNIS tumors by
Discussion
We performed retrovirus-mediated hNIS gene delivery into the F98 rat glioma to investigate hNIS-based tumor imaging and hNIS-based radioiodide therapy. We have shown that F98/hNIS gliomas >4.5 mm in diameter could be imaged in vivo by a gamma scintigraphy using a pinhole collimator. Accumulated radioiodide was retained in F98/hNIS tumor to 24 h after injection of 123 I. Radioiodide uptake in the thyroid gland could be selectively suppressed by T4-supplemental diet. Furthermore, hNIS-based radioiodide therapy may be used as an adjuvant therapy for patients with glioma as the survival of rats with F98/hNIS tumors could be prolonged by 131 I treatment.
Boland et al 13 131 I into nude mice carrying LNCaP/hNIS xenografts resulted in >50% reduction in tumor volume in a late tumor intervention study and complete response in 60% of the tumors in an early tumor intervention study. 17 It is generally believed that the therapeutic effectiveness of radioiodine for patients with thyroid cancer largely depends on the unique ability of thyroid tissues to organify radioiodine. Prolonged radioiodine retention is thought to be essential to achieve sufficient therapeutic dose. However, therapeutic dose delivered to tumors could also be increased by increased radionuclide uptake and the use of alternative radionuclides with more potent radioactivity. It is encouraging that our study showed that the survival of rats with F98/hNIS gliomas was improved by 131 I treatment using an arbitrarily chosen dose. The effectiveness of hNIS-based radionuclide therapy on this animal model may be further improved by using a higher 131 I dose at an earlier intervention time, co-delivery of thyroid peroxidase (TPO) gene to facilitate iodide organification, and/or using alternative hNISmediated substrates, such as 188 ReO 4 . The usefulness of TPO gene transfer for better radioiodide retention in non-thyroidal tumor cells expressing NIS has recently been demonstrated. 18 Transfection of non-small cell lung cancer (NSCLC) cell lines with TPO and NIS resulted in an increase of radioiodide retention and enhanced tumor cell apoptosis upon radioiodide treatment. Very recently, Dadachova et al investigate the feasibility of using the powerful beta-emitting radiometal 188 Re in the form of ReO 4 to enhance local tumor radiation dose compared with 131 I. 19 Using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, the authors showed that 188 ReO 4 is able to deliver a dose 4.5 times higher than 131 I, suggesting that 188 ReO 4 may provide enhanced therapeutic efficacy.
It is interesting to note that rats bearing F98/hNIS tumors not treated with radioiodine had a survival time longer than rats bearing parental F98 tumors or F98/LXSN tumors. Although, this may be due to a clonal selection effect, our unpublished data show that hNIStransduced SK-N-SH (human neuroblastoma) and MATLyLu (rat prostate carcinoma) cells also have a slower tumor growth rate in subcutaneous xenograft animal models compared with their respective parental or vector transduced tumors. This decreased proliferation of hNIStransduced tumor cells might be due to an increased uptake of iodide and sodium into the tumor cells, which in turn may have an inhibitory effect on cell growth. Alternatively, the host immune response to overexpressed hNIS might slow down the tumor cell proliferation resulting in longer survival of F98/hNIS without 131 I treatment. However, we did not see evident infiltrating lymphocytes surrounding the F98/hNIS tumors upon histological examination. Further studies are needed to elucidate the mechanism of the reduced proliferation rate of hNIS-transduced tumors in vivo.
While there is a difference in survival among different experimental groups, the tumor sizes upon death were not significantly different among different rats. We, therefore, interpret that NIS expression and 131 I treatment did have cytostatic and/or cytoreductive effect(s) upon F98 glioma. The longer survival of rats bearing F98/hNIS gliomas may be due to a decreased tumor growth rate in vivo. In humans, clinical symptoms with intracerebral tumors are often to a large degree caused by the surrounding edema in normal tissues. It is not known whether hNIS expression and/or 131 I treatment has an effect on the degree of edema surrounding the tumors. We did not see any evident brain edema in our study upon histological examination.
Targeted radionuclide therapy, such as radioimmunotherapy, as an adjuvant therapy in patients with lymphoma has been proven effective. 20 Therefore, there is much interest to develop genetically targeted radionuclide therapy for selected tumors. 21 Clinical translation of this approach awaits extensive investigations on biodistribution of the selected radionuclides in vivo, as well as detailed dosimetry data to evaluate the therapeutic efficacy versus normal tissue radiotoxicity. This information will be instrumental to develop the optimized therapeutic regimens of the maximal tolerable dose and the favorable dose fractionation. Our study warrants further investigating tumor imaging and therapeutic strategies based on NIS gene transfer followed by radionuclide administration in a variety of human cancers.
Materials and methods
Cell culture
The F98 rat glioma cell line was derived from an undifferentiated neoplasm transplacentally induced by N-ethyl-N-nitrosourea in an inbred CD Fischer rat and has been Gene Therapy propagated in vitro and in vivo since 1971. Its morphology and growth characteristics have been described in detail. [22] [23] [24] The F98 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL, Gaithersberg, MD, USA) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 0.1 mM non-essential amino acids, 10 units/ml penicillin, and 10 g/ml streptomycin (Gibco-BRL). Transduced F98 glioma cells were maintained in media containing 350 g/ml Geneticin (G418) (Gibco-BRL). A retroviral packaging cell line, PA317 (American Type Culture Collection, ATCC, Manassas, VA, USA) was maintained in DMEM with high glucose and L-glutamine supplemented with 10% fetal bovine serum, 10 units/ml penicillin, and 10 g/ml streptomycin.
Production of recombinant retrovirus containing hNIS
A full length hNIS cDNA fragment was inserted into the pLXSN retroviral vector, 25 such that the Moloney murine leukemia virus long terminal repeat (LTR) promoter drives hNIS expression and the SV40 promoter drives Neo r expression (a construct referred to as L-hNIS-SN, see Figure 1a ).
PA317 retroviral packing cells were transfected with 10 g of L-hNIS-SN or LXSN DNA, respectively, using the calcium-phosphate precipitation method. Selection was performed using 750 g/ml G418 (Gibco BRL) in the medium for 5 days, followed by maintenance in medium containing 350 g/ml G418. Starting 11 days after transfection, individual drug-resistant PA317/L-hNIS-SN or PA317/LXSN clones were isolated, expanded, and tested for NIS function by in vitro RAIU assay. 11 Viral supernatant was harvested every 12 h until cells reached 80-100% confluence, and centrifuged at 3000 g for 5 min at 4°C to remove cellular debris, and stored at Ϫ80°C.
Retrovirus-mediated hNIS transduction of F98 cells
As a proof of concept experiment, we performed ex vivo hNIS gene transfer mediated by recombinant retrovirus. F98 cells were infected with the L-hNIS-SN recombinant retrovirus. After G418 selection (700-750 g/ml), individual clones were isolated, expanded, and maintained in medium containing 350 g/ml of G418, and frozen in liquid nitrogen. Each F98/hNIS clone was tested for NIS function by an in vitro RAIU assay. One of the clones that showed >40-fold increase of RAIU activity was used for the in vivo experiments described in the following section. As a negative control, F98 cells transduced with retrovirus containing the LXSN vector alone were also selected.
Intracerebral F98 brain tumor model
Fischer rats weighing 175 to 200 g (Harlan Sprague Dawley, Indianapolis, IN, USA) were stereotactically implanted with tumor cells. 16, 26 All experimental procedures received approval from Institutional Laboratory Animal Care and Use Committee of the Ohio State University. Briefly, rats were sedated by intraperitoneal (i.p.) administration of 120 mg of ketamine/20 mg of xylazine (Fort Dodge, Fort Dodge, IA, USA) per kg of body weight, after which a plastic screw (Arrow Machine Manufacturing, Richmond, VA, USA) was embedded into the cranium. F98 cells were injected within 10 to 15 s through a central hole in the plastic screw into the right hemisphere at a concentration of 10 3 (for therapeutic study) or 10 5 (for imaging study) cells in 10 l of serumfree DMEM containing 1.4% agarose with a gelling temperature of Ͻ30°C. The screw hole was filled with bone wax immediately following withdrawal of the needle, and the operative field was flushed with betadine before the scalp incision was closed with a single sterilized clip.
Immunohistochemical (IHC) staining and Western blot analysis
Immunohistochemical staining was performed as previously described, 27 with some modifications. Briefly, tissue sections were incubated with hNIS polyclonal antibodies #331 (1:1000 dilution) at room temperature for 1 h, and then incubated with biotinylated goat anti-rabbit IgG (1:200 dilution, Vector Laboratories, Burlingame, CA, USA) for 20 min. Western blot analysis was performed as previously described. 28 Briefly, the transferred filter was incubated with an anti-hNIS antibody #331 (1:3000 dilution) or anti-rNIS peptide polyclonal antibody pAb 716 (1:4000 dilution) for 1.5 h at room temperature, followed by incubation with peroxidase (HRP)-conjugated donkey anti-rabbit IgG (1:3000 dilution) for 1 h at room temperature. For deglycosylation of the proteins, denatured proteins were treated with 1 l (500 U) of Peptide: N-glycosidase F (PNGase F) (New England Biolabs, Beverly, MA, USA) in 50 mM sodium phosphate buffer (pH 7.5) containing 1% Nonidet P-40 at 37°C for 1 h.
Tumor imaging
Rats were anesthetized by i.p. injection of ketamine/xylazine, and then 2.0 mCi of 99m TcO 4 in 0.2 ml volume was administered via tail vein injection. Approximately 20 min after injection, rats were imaged with a dual head gamma camera (Picker Prism 2000; Marconi Medical Systems, Cleveland, OH, USA) equipped with a pinhole collimator and a low energy ultra high-resolution parallel hole collimator (LEUHR) on each head of the gamma camera, respectively. Vertex and right lateral views with at least 500 000 total counts per image, were collected. Image acquisition times ranged from 2 to 3 min.
The average survival time for rats implanted with 10 5 F98/hNIS glioma cells is about 14-16 days. For studies of 123 I retention, images were acquired on days 13 to 15 following tumor implantation at which time 123 I (0.25 mCi) was administered via tail vein injection. Modified conjugate images were obtained sequentially with the rat first in dorsal-ventral and then ventral-dorsal positions on the top of the LEUHR collimator at 5 min, 20 min, 1 h, 4 h, 24 h and 37 h following injection. The acquisition time at 5 min after injection image was 5 min, and the acquisition times at subsequent time-points were corrected for the physical decay of 123 I. Regions of interest (ROI) were drawn over the tumor, thyroid, and shoulder region (as a background) in two views (vertex and then ventral) of pinhole images for each different time-point, and the geometric means of the count rates (counts/pixel) for each ROI in each view were calculated. Biological half-life of radioiodine was estimated based on the time activity curve generated by plotting the tumor ROI count rates versus time. I per injection, on days 12, 14 and 16 after implantation for a total of 12 mCi. The tumor size index on day 14 was assumed to be~2 mm 2 based on a previous study. 29 Animals were weighed three times per week. The combination of sustained weight loss, ataxia and periorbital hemorrhage indicated that death was imminent. 26, 29 Therefore, animals displaying these signs were killed, and survival times were determined from the day of tumor implantation to the day of death plus 1 day. 26, 29 The observers were not blinded to kill the rats. To confirm that all animals had progressively growing tumors at the time of death, the brains were removed, fixed in 10% neutral buffered formalin, and then 2-mm coronal sections were cut with a rat brain slicer (ZivicMiller Laboratories, Allison Park, PA, USA), and processed for routine histopathological examination. Tumor size was measured as (the longest length) × (the length perpendicular to the longest length) in tumor sections. Survival among different experimental groups was compared using unpaired t test, as well as log-rank test. Tumor sizes among different experimental groups were compared using unpaired t test. The P value of Ͻ0.05 were considered statistically significant.
I therapeutic studies
